Disease relevance of FENPROSTALENE

• In this study, 90% of animals treated with fenprostalene calved within a 20-h period, but with a high incidence of retained placenta [1].
• Following the injection of fenprostalene, side effects such as salivation, vomiting, colic symptoms, and watery diarrhea occurred most frequently (80-100% of cases) in group I bitches [2].
• Postpartum plasma PGF metabolite profile in cows with dystocia and/or retained placenta, and effect of fenprostalene on uterine involution and reproductive performance [3].

High impact information on FENPROSTALENE

• EP and FP receptor upregulation was associated with corresponding increases in IP3 production and retinal vasoconstriction in response to PGF2alpha, fenprostalene (an FP agonist), PGE2, 17-phenyl trinor PGE2 (an EP1 agonist), and M&B28,767 (an EP3 agonist) and with enhanced RBF autoregulation of high BP (> or =125 mm Hg) [4].
• The kinetics of degradation of fenprostalene (I) in polyethylene glycol 400 solution was examined using HPLC [5].
• Cows that received fenprostalene consumed more dry matter (DM) for the last 8 d prepartum than did cows that did not receive fenprostalene (9.6 kg/d vs. 8.5 kg/d, respectively) but consumed less DM for the first 10 d postpartum (10.9 kg/d vs. 13.1 kg/d, respectively) [6].
• PROCEDURE: Cows were assigned within 2 hours after calving to serve as untreated control cows or to be treated with 1 mg of fenprostalene, SC; 25 mg of dinoprost tromethamine, IM; or 20 IU of oxytocin, IM [7].
• Estradiol-17 beta benzoate did not reduce incidence of retained placenta in animals treated with fenprostalene (group B vs. group D) but tended to reduce incidence in uninduced animals (group A vs. group C) [1].

Chemical compound and disease context of FENPROSTALENE

• The incidence of placenta retained for >24 h was higher for induced than spontaneous parturition (21.0 vs 0.0%), but it did not differ (P >0.1) between cows treated with prostaglandin F(2alpha) or fenprostalene (19.2 vs 22.6%) [8].

Biological context of FENPROSTALENE

• Twelve of 14 Day-2 cows and all Day-10 cows exhibited estrus after fenprostalene treatment [9].
• Average length of the first estrous cycle after the fenprostalene injection was 11.2, 8.3, 9.7 and 19.1 for Groups 1, 2, 3 and 5, respectively [10].
• Induction of parturition in goats with fenprostalene [11].
• Fenprostalene (at luteolytic dosage) was not uterokinetic in either the cyclic or postpartum cow [12].
• Ninety-one to 100 per cent of pregnant sows injected with 0.25, 0.5 or 1 mg of fenprostalene on days 112, 113 or 114 of gestation began to farrow within 30 hours of treatment, the majority during working hours on the day after injection [13].

Anatomical context of FENPROSTALENE

• These long-lasting oxytocic properties, in addition to its luteolytic capabilities, would make fenprostalene a suitable drug for promoting effective evacuation of the uterus when required in daily veterinary practice [14].
• The oxytocic effect of a prostaglandin F2 alpha analogue, fenprostalene, was assessed in 4 ovariectomized ewes fitted with electrodes in both uterine horns and in the cervix [14].

Associations of FENPROSTALENE with other chemical compounds

• Calving response did not differ (P >0.1) between cows treated with prostaglandin F(2alpha) versus fenprostalene (36.5 +/- 1.6 vs 38.6 +/- 1.6 h) or among cow age, day of gestation, or breed [8].
• Uterokinetic activity of fenprostalene (a prostaglandin F2alpha analog) in vivo and in vitro in the bovine [12].
• The calving percentages (for cows and heifers combined) that resulted from artificial insemination (AI) were 32.3, 31.4, 43.6, and 51.1% for the control, fenprostalene, cloprostenol sodium, and PGF(2alpha) groups, respectively [15].
• Also, during normal estrous cycles, 5/10 and 0/8 fenprostalene- and cloprostenol-treated heifers, respectively, showed progesterone concentrations higher than 1 ng/mL 48 h after treatment [16].
• On d 276 of gestation, 14 animals (9 cows and 5 heifers) per group received a placebo (group A), 1 mg of fenprostalene (group B), 50 mg of estradiol-17 beta benzoate (group C), or both (group D) [1].

Gene context of FENPROSTALENE

• However, fenprostalene-desensitized (by exposure to fenprostalene) uteri reacted significantly to oxytocin, and vice versa [12].

Analytical, diagnostic and therapeutic context of FENPROSTALENE

• Each treatment consisted of a subcutaneous injection of 1.0 mg fenprostalene [17].
• Conversely, fenprostalene induced calving approximately 2 d after treatment [1].
• Treatment with fenprostalene (groups 2 and 3) decreased the number of cows with a palpable uterine lumen detectable during per rectal palpation at 28 to 42 days after parturition [18].
• Administration of 50 microg or more of fenprostalene induced abortion in all dogs 3 to 13 days after the treatment [19].

References